Second Annual Medical Imaging for Clinical Trials

Oct 27th, 2004Oct 28th, 2004
Philadelphia, PA
US
https://www.cbinet.com
Leverage medical imaging and surrogate endpoints to decrease cost and time to market for oncology and arthritis therapeutics.
Latest in Home
Alz D
MRI detects ARIA in 21% of real-world donanemab patients
August 24, 2026
Shutterstock 398149600
What independent clinics need to know before buying a CT scanner
August 24, 2026
Nominations Are Open — 2026 Minnies
Sponsored
Nominations Are Open — 2026 Minnies
August 6, 2026
Food Insecurity
Food insecurity linked to higher risk of death in breast cancer
August 21, 2026
More in Home
MRI detects ARIA in 21% of real-world donanemab patients
By Will Morton
Of the 48 patients who underwent at least one surveillance MRI, 10 (21%) had an ARIA detected.
August 24, 2026
Alz D
What independent clinics need to know before buying a CT scanner
By Joe Mason, Brandon Bush
In a new column, Brandon Bush and Joe Mason of Arineta offer CT purchasing advice for independent practices.
August 24, 2026
Shutterstock 398149600
Radiotherapy access could address gynecological cancer disparities
By Amerigo Allegretto
Inadequate radiotherapy infrastructure is one of several drivers of gynecological cancer disparities in LMICs.
August 24, 2026
Radiotherapy 400
Food insecurity linked to higher risk of death in breast cancer
By Will Morton
Food-insecure regions are where people lack consistent access to enough affordable, nutritious food.
August 21, 2026
Food Insecurity
How much surveillance imaging is needed for meningiomas?
By Amerigo Allegretto
Most surveillance MRI or CT exams did not result in intervention, and treatment rates remained stable during the study period.
August 21, 2026
Mri Slide 400
Ultrasound MinnieCast, Episode 15: Wearable ultrasound making strides
By Amerigo Allegretto
Geonho (Tom) Park, PhD, from Stanford Medicine shares insights from the work he and colleagues have done in wearable ultrasound.
August 21, 2026
Minnie Cast Thumbnail (20)
PET/CT outperforms MRI after focal therapy for prostate cancer
By Will Morton
No accurate noninvasive method has been validated to evaluate treatment response after focal therapy.
August 20, 2026
True-positive PSMA-PET with positive MRI in 74-year-old male with prostate cancer (Gleason score of 4 + 5; left anterior and posterior apex positive cores). (A) Left posterior peripheral apical to midprostate hyposignal visible on transaxial MRI. (B) No definite CT correlate evident (white arrow). (C) Focal high PSMA expression detectable in left posterior mid to base with SUVmax of 12.4 on transaxial fused delayed pelvic PET/CT (yellow arrow). (D) Focal high PSMA expression found in left midgland to base of prostate on maximum-intensity-projection image (yellow arrow).
Florida approves NBPAS as recognized board certification option
By AuntMinnie.com staff writers
NBPAS-certified physicians can now represent themselves as board certified in Florida physician advertising.
August 20, 2026
Florida Sign 400
Thermal ablation achieves long-term survival in kidney cancer
By Will Morton
The 10-year overall survival (OS) and cancer-specific survival (CSS) rates were 68.5% and 75.5%.
August 20, 2026
Kidney2
Most FDA-cleared AI medical devices not tested on patient outcomes
By Amerigo Allegretto
Of the 1,059 FDA-cleared devices used in radiology, three had a registered trial.
August 19, 2026
Artificial Intelligence Ai Global Communication Network 400
AI framework could improve MRI quality control in prostate cancer
By Amerigo Allegretto
The framework uses a DL model trained on low- and high-quality MR images and helped improve radiologist accuracy.
August 19, 2026
Low-quality axial T2-weighted MRI scans with gradient-weighted class activation mapping. The low-quality MRI scans (top row) show blurred structures and artifacts making zonal and capsule boundaries indistinguishable. On the same scans with gradient-weighted class activation map overlays (bottom row), red indicates regions that were most heavily weighted by the deep learning model toward the low-quality prediction.
New immuno-PET tracer shows promise in lung cancer
By Will Morton
Molecular imaging can provide whole-body visualization and quantitative assessment of PD-L1 expression.
August 18, 2026
(A) Ga-68 NK224 PET/CT maximum intensity projection image (left), axial PET/CT images (center), and axial CT images (right) in a 43-year-old female participant with lung adenocarcinoma show lesions in the right cerebellum (blue arrow), right frontal lobe (red arrow), and sternum (green arrow) with low, intermediate, and high tracer uptake, respectively. Photomicrographs (scale bar, 100 μm) with hematoxylin-eosin (H&E) staining (center bottom) and programmed death ligand 1 (PD-L1) immunohistochemical (IHC) staining (right bottom) show high PD-L1 expression in the sternal lesion (tumor proportion score ≥ 50%).
Page 1 of 245
Next Page